drugset / Trial / NCT01968798
ASPREE Cancer Endpoints Study
Phase 4
Unknown
14500 enrolled
Hennepin Healthcare Research Institute
Bayer · collabBerman Center for Outcomes and Clinical Research · collabMonash University · collabNational Cancer Institute (NCI) · collabNational Health and Medical Research Council, Australia · collabNational Institute on Aging (NIA) · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The ASPREE Cancer Endpoint Study (ACES), an ancillary study of the ASPirin in the Prevention of Events in the Elderly (ASPREE) Study, will allow for the examination of the effect of daily low-dose aspirin (100 mg) compared to placebo, on specific DNA biomarkers and selected specific incident and recurrent cancer and metastases. The establishment of this ACES biobank will allow for the exploration of DNA-related molecular mechanisms of aspirin's protective effect against cancer, cancer associated mortality and metastases, using blood or saliva DNA specimens, urine, and tumor tissue.
Timeline
- Start
- 2013-09
- Primary completion
- 2019-01
- Completion
- 2024-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aspirin | Small molecule | 100 mg | — |